External Validation of the Michigan Barrett's Esophagus Prediction Tool

Aaron P. Thrift*, Thomas L. Vaughan, Lesley A. Anderson, David C. Whiteman, Hashem B. El-Serag

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

16 Citations (Scopus)


Barrett’s esophagus (BE) is a premalignant lesion for esophageal adenocarcinoma, a rapidly increasing, highly fatal cancer.1 Clinical guidelines recommend screening for BE in those with chronic gastroesophageal reflux disease (GERD) and at least 2 risk factors (eg, >50 years of age, white race, obese, tobacco smoking history).2, 3 However, providing clinicians with a tool that allows them to estimate a patients’ risk may better aid them in deciding who to screen for BE and make future resource utilization more efficient. The Michigan Barrett’s Esophagus pREdiction Tool (M-BERET) predicts risk for BE in men attending primary care using information on their frequency of GERD symptoms, age, waist-to-hip ratio (WHR), and pack-years of cigarette smoking.4 In internal validation, the M-BERET discriminated reasonably well between men with and without BE, with an area under the receiver-operating characteristic curve (AUROC) of 0.72. This was significantly better than using GERD symptoms alone (0.72 vs 0.61; P < .001).4 However, this prediction tool needs to be validated in an independent population before its use can be recommended in clinical practice.
Original languageEnglish
Pages (from-to)1124-1126
Number of pages3
JournalClinical Gastroenterology and Hepatology
Issue number7
Early online date12 Mar 2017
Publication statusPublished - Jul 2017

Bibliographical note

This work was supported by the National Institutes of Health R01 CA116845 (HES); K24-04-107 (HES); an Ireland–Northern Ireland cooperation research project grant sponsored by the Northern Ireland Research and Development Office and the Health Research Board, Ireland (for FINBAR; RES/1699/01N/S); the Study of Digestive Health, NCI RO1 CA 001833 (DCW); the Study of Reflux Disease, NCI R01 CA72866 (TLV); and the Established Investigator Award in Cancer Prevention and Control, K05 CA124911 (TLV).


Dive into the research topics of 'External Validation of the Michigan Barrett's Esophagus Prediction Tool'. Together they form a unique fingerprint.

Cite this